FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVIB APPROVAL								
OMB Number:	3235-028							
Estimated average but	rden							
hours per response	0.							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response	s)			Ī				-,											
1. Name and Address of Reporting Person Chadha Deepak (Last) (First) (Middle) C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102 (Street) BOULDER, CO 80301				2. Issuer Name and Ticker or Trading Symbol Brickell Biotech, Inc. [BBI]									5. R	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Chief Research & Dev. Officer						
				3. Date of Earliest Transaction (Month/Day/Year) 09/15/2020 4. If Amendment, Date Original Filed(Month/Day/Year)								X								
												6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person								
(Cit	y)	(State)		(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y			e	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		(<i>I</i>	4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5) (A) or Amount (D)			Own Tran (Inst		ecurities Beneficially ng Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership			
Reminder:	Report on a s	separate line for eac	h class					ectly o	or indir P in a	ectly. ersons this f	s who re orm are tly valid	spond not re	to to	he col ed to i trol ni	respond u umber.		on containe form displa	ed SEC	C 1474 (9-02)	
		1			(e.g., p		Securiti calls, wa	rrants	s, opti	ons, coi	vertible	securi	ties)				1			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu any	Execution Date, if		Transaction Deriv Code Secur (Instr. 8) Acqui		ties red (A) posed of 3, 4,			Date		7. Title and of Underlyin Securities (Instr. 3 and		ing		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owner Form of Deriva Securit Direct or Indi	of Benefic Owners (y: (Instr. 4)	
						Code V (A)		(D)		cisable	Expirati Date	on	Title		Amount or Number of Shares		(Instr. 4)	(Instr.	*)	
Stock Option (right to buy)	\$ 0.8	09/15/2020			A		400,00	00		(1)	09/15/2	2030		nmon ock	400,000	\$ 0	400,000	D		
Repor	ting O	wners																		
Director			Relationships								_									
			0% wner	Officer					Othe	er										
Chadha Deepak C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUITE 102 BOULDER, CO 80301				Chief Research & Dev. Officer																
Signa	tures																			
/s/ Chris	tine G. Lo	ng, Attorney-in-	Fact fo	or Chadha	Deepal	k (p	ower of	attor	ney p	orevio	usly file	ed)		09	9/16/2020					
			Sig	nature of Reporti	ng Person										Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock options will vest 25% on September 15, 2021, and the remainder will vest in equal monthly installments over the following three very vears

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are no	ot required to respond unless the form displays a currently valid OMB number.